Risk Cmte. Member Furberg Is On Record Pro Long Trials, Con Pfizer Drugs

FDA's new risk management subcommittee has a prominent and widely published member with strong predilections for long clinical trials showing clear clinical benefit, especially for follow-on compounds in an established class